These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 25402193

  • 1. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S, Gozukara I, Aksoy A, Uludag EU, Keskin H, Kamalak Z, Carlioglu A.
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [Abstract] [Full Text] [Related]

  • 2. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA.
    Diabetes Metab Syndr; 2016 Dec; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [Abstract] [Full Text] [Related]

  • 3. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 4. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, Diamanti-Kandarakis E.
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [Abstract] [Full Text] [Related]

  • 5. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 6. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I.
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [Abstract] [Full Text] [Related]

  • 7. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [Abstract] [Full Text] [Related]

  • 8. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
    Carlioglu A, Kaygusuz I, Karakurt F, Gumus II, Uysal A, Kasapoglu B, Armutcu F, Uysal S, Keskin EA, Koca C.
    Arch Gynecol Obstet; 2014 Nov; 290(5):929-35. PubMed ID: 24840107
    [Abstract] [Full Text] [Related]

  • 9. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
    Harborne L, Fleming R, Lyall H, Sattar N, Norman J.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4116-23. PubMed ID: 12970273
    [Abstract] [Full Text] [Related]

  • 10. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF.
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [Abstract] [Full Text] [Related]

  • 11. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [Abstract] [Full Text] [Related]

  • 12. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
    Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC.
    Eur J Endocrinol; 2005 Feb; 152(2):269-75. PubMed ID: 15745936
    [Abstract] [Full Text] [Related]

  • 13. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 14. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
    Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
    [Abstract] [Full Text] [Related]

  • 15. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
    Elter K, Imir G, Durmusoglu F.
    Hum Reprod; 2002 Jul; 17(7):1729-37. PubMed ID: 12093831
    [Abstract] [Full Text] [Related]

  • 16. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 17. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
    Sahu A, Tripathy P, Mohanty J, Nagy A.
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
    [Abstract] [Full Text] [Related]

  • 18. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
    Lin XF, Wu RR, Du J, Liao YC, Du Y, Ye Y, Wang Y, Zhang XB, Wu C, Chen A.
    Clin Exp Obstet Gynecol; 2015 May; 42(3):315-20. PubMed ID: 26152001
    [Abstract] [Full Text] [Related]

  • 19. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome.
    Karabulut A, Demirlenk S, Sevket O.
    Gynecol Endocrinol; 2012 Apr; 28(4):245-8. PubMed ID: 21961995
    [Abstract] [Full Text] [Related]

  • 20. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F, Carlioglu A, Kaygusuz I, Gumus II, Uz B, Akdeniz D.
    Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.